| Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv51-iv67, 2018 | 950 | 2018 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ... Annals of Oncology 32 (11), 1348-1365, 2021 | 717 | 2021 |
| Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of oncology 29, iv68-iv78, 2018 | 645 | 2018 |
| Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a … JS Gold, M Gönen, A Gutiérrez, JM Broto, X García-del-Muro, TC Smyrk, ... The lancet oncology 10 (11), 1045-1052, 2009 | 630 | 2009 |
| Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ... Annals of Oncology 29, iv79-iv95, 2018 | 601 | 2018 |
| Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label … A Gronchi, S Ferrari, V Quagliuolo, JM Broto, AL Pousa, G Grignani, ... The Lancet Oncology 18 (6), 812-822, 2017 | 492 | 2017 |
| Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study … J Martín, A Poveda, A Llombart-Bosch, R Ramos, JA López-Guerrero, ... Journal of Clinical Oncology 23 (25), 6190-6198, 2005 | 430 | 2005 |
| An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma PAtients EuroNet (SPAEN) and European organization for … B Kasper, C Baumgarten, J Garcia, S Bonvalot, R Haas, F Haller, ... Annals of Oncology 28 (10), 2399-2408, 2017 | 418 | 2017 |
| Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ... The Lancet 394 (10197), 478-487, 2019 | 397 | 2019 |
| Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, ... Annals of oncology 33 (1), 20-33, 2022 | 393 | 2022 |
| Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research … X García-del-Muro, A López-Pousa, J Maurel, J Martín, J Martínez-Trufero, ... Journal of Clinical Oncology 29 (18), 2528-2533, 2011 | 317 | 2011 |
| Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up SJ Strauss, AM Frezza, N Abecassis, J Bajpai, S Bauer, R Biagini, ... Annals of Oncology 32 (12), 1520-1536, 2021 | 292 | 2021 |
| Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial WD Tap, AJ Wagner, P Schöffski, J Martin-Broto, A Krarup-Hansen, ... Jama 323 (13), 1266-1276, 2020 | 263 | 2020 |
| Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases J Lasota, CL Corless, MC Heinrich, M Debiec-Rychter, R Sciot, ... Modern pathology 21 (4), 476-484, 2008 | 247 | 2008 |
| Outcome of patients with platelet-derived growth factor receptor alpha–mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era PA Cassier, E Fumagalli, P Rutkowski, P Schöffski, M Van Glabbeke, ... Clinical Cancer Research 18 (16), 4458-4464, 2012 | 245 | 2012 |
| Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group A Gronchi, S Frustaci, M Mercuri, J Martin, A Lopez-Pousa, P Verderio, ... Journal of clinical oncology 30 (8), 850-856, 2012 | 224 | 2012 |
| Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group S Stacchiotti, A Gronchi, P Fossati, T Akiyama, C Alapetite, M Baumann, ... Annals of Oncology 28 (6), 1230-1242, 2017 | 220 | 2017 |
| Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups A Gronchi, E Palmerini, V Quagliuolo, J Martin Broto, A Lopez Pousa, ... Journal of Clinical Oncology 38 (19), 2178-2186, 2020 | 219 | 2020 |
| GEIS guidelines for gastrointestinal sarcomas (GIST) A Poveda, XG Del Muro, JA López-Guerrero, R Cubedo, V Martínez, ... Cancer treatment reviews 55, 107-119, 2017 | 186 | 2017 |
| Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and … PG Casali, A Le Cesne, A Poveda Velasco, D Kotasek, P Rutkowski, ... Journal of Clinical Oncology 33 (36), 4276-4283, 2015 | 186 | 2015 |
